Friday, 21 Sep 2018

Biologic/Novel Rx

Datesort ascending Type Title Save
07 Sep 2017 Social An approved biosimilar by regulatory authorities neither better nor worse in efficacy/safety to its bio-originator. https://t.co/cxWtoUsmwW
07 Sep 2017 News New Recommendations on Biosimilar Use
07 Sep 2017 Social In 10yrs MTX/biologic use increased (40%/1.7% to 64%/27%) & rate of ortho surgery dropped (72 to 51/1000 pts in 2014 https://t.co/IE72n2YMPB
06 Sep 2017 Social US patent office has issued two patents for janus kinase(JaK) inhibitors for hair loss. https://t.co/TReKaoFUwy
30 Aug 2017 News Turnabout for Baricitinib
29 Aug 2017 Social 25 studies shows low risk of HBV reactivation (1.6%) w/ resolved HBV - not changed by TNFi, other biologics, DMARDs https://t.co/wzjikRHPFh
28 Aug 2017 Social Severe (ocular) Behcets study: ~half respond to TNF inhib but only half these stay in remission w/ TNFi withdrawal https://t.co/a2oGZADlle
28 Aug 2017 News Canakinumab Reduces CV Outcomes in High Risk Patients
28 Aug 2017 Social RT @DanielHSolomon: Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease — NEJM how will this affect rheumatology? https:/…
22 Aug 2017 Social RT @RheumKay: What's harder than making copycat biotech drugs? Selling them https://t.co/gMHACs9RpN via @markets
22 Aug 2017 Social Korean companies Celltrion & Samsung Bioepis have exported $1.63 Billion in Biosimilars in 2016. https://t.co/JHBQqJSV6h
21 Aug 2017 Social Ironwood announces FDA approval of its combo drug lesinurad/allopurinol in a 200/300 tablet. Could this be useful? https://t.co/lcUZTieKqg
21 Aug 2017 Social FDA CDER list of licensed biologics and biosimilars updated Aug 2017 https://t.co/bIFmjPsId7
19 Aug 2017 Social RheumNow Wk in Review up! How to store enbrel, over/under testing. Check out podcast https://t.co/I5b8tFK7Oa video https://t.co/rJ2nMY6woD
14 Aug 2017 Social Tocilizumab in Scleroderma completed enrollment in phase III trial - another yr till skin + lung results https://t.co/6QVGeDScbv
08 Aug 2017 Social Tanezumab (MAb against nerve growth factor) is being fast-tracked by FDA as a non-opioid pain reliever. https://t.co/ZXJnS7CmE4
08 Aug 2017 News Therapeutic Update: 5 Questions on Sirukumab FDA Hearing
06 Aug 2017 Social When biosimilars are available, when will you prescribe them?
06 Aug 2017 Social RheumNow Wk in Review is up! FDA hearings on sirukumab, tofacitinib. iTUNES, podcast https://t.co/rX1zLRHUuA & video https://t.co/slvfTJYR1E
03 Aug 2017 News Arthritis Advisory Panel Votes Down Sirukumab